The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1390
ISSUE1390
May 14, 2012
Fentanyl Sublingual Spray (Subsys) for Breakthrough Cancer Pain
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Fentanyl Sublingual Spray (Subsys) for Breakthrough Cancer Pain
May 14, 2012 (Issue: 1390)
The FDA has approved a sublingual spray formulation of
fentanyl (Subsys – Insys) for management of breakthrough
pain in adult cancer patients who are receiving
and are tolerant to opioid therapy (taking ≥60 mg/day of
oral morphine or the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.